Intrahepatic flow diversion prior to segmental Yttrium-90 radioembolization for challenging tumor vasculature

Lindsay B. Young, Marcin Kolber, Michael J. King, Mona Ranade, Vivian L. Bishay, Rahul S. Patel, Francis S. Nowakowski, Aaron M. Fischman, Robert A. Lookstein, Edward Kim

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background: Hepatic tumors with complex vascular supply or poor relative perfusion are prone to decreased rates of objective response. This is compounded in the setting of Yttrium-90 (Y90) transarterial radioembolization (TARE), which is minimally embolic and flow-dependent, relying on high threshold dose for complete response. Objective: We describe our experience with intrahepatic flow diversion (FD) prior to TARE of hepatocellular carcinoma (HCC) with challenging vascular supply. Materials and methods: Between April 2014 and January 2020, 886 cases of coinciding MAA or TARE and bland embolization or temporary occlusion were identified. Intraprocedural embolizations performed for more routine purposes were excluded. FD was performed by bland embolization or temporary occlusion of vessels supplying non-malignant parenchyma in cases where flow was not preferential to target tumor. Lesion characteristics, vascular supply, treatment approach, angiography, and adverse events (AEs) were reviewed. Radiographic response was assessed using mRECIST criteria. Results: 22 cases of FD of focal HCC were identified. Embolics included calibrated microspheres (n ​= ​11), microcoils (n ​= ​4), gelfoam (n ​= ​3), temporary balloon occlusion (n ​= ​2) and temporary deployment of a microvascular plug (n ​= ​1). Post-treatment SPECT-CT dosimetry coverage was concordant with target lesions in all cases. Mean follow-up was 16.7 months (1.4–45 ​mos). Tumor-specific response per mRECIST was 41% complete response, 50% objective response, and 59% disease control rate. No major adverse events or grade 3/4 hepatotoxicity were reported. Conclusion: Our findings suggest that FD prior to TARE is safe and potentially effective in treating HCC with complex vascular supply or poor tumor perfusion.

Original languageEnglish
Pages (from-to)79-83
Number of pages5
JournalJournal of Interventional Medicine
Issue number2
StatePublished - May 2022


Dive into the research topics of 'Intrahepatic flow diversion prior to segmental Yttrium-90 radioembolization for challenging tumor vasculature'. Together they form a unique fingerprint.

Cite this